Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Once-Daily Stavudine XR Regimen in HIV
NCT00135369Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2002
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of stavudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of subjects with plasma HIV-1 levels <50 copies/mL at 48 weeks. Started Sep 2002; status: completed.
02
Drugs
stavudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00135369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135369.